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Abstract
Background
Sri Lankan Russell’s viper (Daboia russelii) envenoming is reported to cause myotoxicity
and neurotoxicity, which are different to the effects of envenoming by most other populations
of Russell’s vipers. This study aimed to investigate evidence of myotoxicity in Russell’s viper
envenoming, response to antivenom and the toxins responsible for myotoxicity.
Methodology and Findings
Clinical features of myotoxicity were assessed in authenticated Russell’s viper bite patients
admitted to a Sri Lankan teaching hospital. Toxins were isolated using high-performance liq-
uid chromatography. In-vitro myotoxicity of the venom and toxins was investigated in chick
biventer nerve-muscle preparations. Of 245 enrolled patients, 177 (72.2%) had local myal-
gia and 173 (70.6%) had local muscle tenderness. Generalized myalgia and muscle tender-
ness were present in 35 (14.2%) and 29 (11.8%) patients, respectively. Thirty-seven
patients had high (>300 U/l) serum creatine kinase (CK) concentrations in samples 24h
post-bite (median: 666 U/l; maximum: 1066 U/l). Peak venom and 24h CK concentrations
were not associated (Spearman’s correlation; p = 0.48). The 24h CK concentrations differed
in patients without myotoxicity (median 58 U/l), compared to those with local (137 U/l) and
generalised signs/symptoms of myotoxicity (107 U/l; p = 0.049). Venom caused concentra-
tion-dependent inhibition of direct twitches in the chick biventer cervicis nerve-muscle prep-
aration, without completely abolishing direct twitches after 3 h even at 80 μg/ml. Indian
polyvalent antivenom did not prevent in-vitro myotoxicity at recommended concentrations.
Two phospholipase A2 toxins with molecular weights of 13kDa, U1-viperitoxin-Dr1a (19.2%
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of venom) and U1-viperitoxin-Dr1b (22.7% of venom), concentration dependently inhibited
direct twitches in the chick biventer cervicis nerve-muscle preparation. At 3 μM, U1-viperi-
toxin-Dr1a abolished twitches, while U1-viperitoxin-Dr1b caused 70% inhibition of twitch
force after 3h. Removal of both toxins from whole venom resulted in no in-vitro myotoxicity.
Conclusion
The study shows that myotoxicity in Sri Lankan Russell’s viper envenoming is mild and non-
life threatening, and due to two PLA2 toxins with weak myotoxic properties.
Author Summary
There are many gaps in our knowledge of muscle damage caused by snake venoms. Rus-
sell’s vipers are more medically important than any other snake in Asia. Sri Lankan Rus-
sell’s viper (Daboia russelii) bites have been reported to cause muscle damage in humans,
which is not reported for other Russell’s vipers. The aim of the present study was to inves-
tigate the onset, severity and resolution of the muscle damage and to identify the toxins
responsible for myotoxicity. For this, we studied muscle damage in 245 patients with con-
firmed Sri Lankan Russell’s viper bites. Patients reported local muscle pain in 72% of cases
and generalised muscle pain in 15%. None had severe muscle damage and the symptoms
resolved in 80% of patients within 4 days. Measurement of biomarkers of muscle damage
in patient blood was consistent with only mild muscle injury, even in patients with symp-
toms. Two toxins were isolated from Sri Lankan Russell’s viper venom that had similar
myotoxic activity to whole venom in chick muscle preparations. Both toxins were weak
myotoxins, consistent with what was seen in patients.
Introduction
Snake bite is a significant public health issue in the tropics [1]. Coagulopathy, neuromuscular
paralysis, acute kidney injury and local effects are the most important clinical syndromes of
snake envenoming [2]. Russell’s viper bites cause a large number of envenomings across Asia,
and are more medically important than any other snake in the region [3,4]. Both species of
Russell’s vipers, i.e. D. russelii (found in Sri Lanka, India, Pakistan, Nepal, Bangladesh) and D.
siamensis (found in some parts of southeast and east Asia such as Cambodia, Myanmar, Thai-
land, Taiwan, South China and, some parts of Indonesia including East Java), commonly
cause venom-induced consumption coagulopathy, acute kidney injury and mild local effects
throughout their distribution [3,5]. However, there is geographical variation in the clinical
effects of Russell’s viper envenoming with neuromuscular paralysis and rhabdomyolysis only
reported from Sri Lanka and South India [3,6–9]. In a recent clinical and neurophysiological
investigation of neuromuscular paralysis in Sri Lankan Russell’s viper envenoming, we showed
that the paralysis is mild, non-life threatening with no long term effects [6]. Clinical evidence
of myotoxicity, including local and generalized myalgia, muscle tenderness, and dark red or
black coloured urine suggestive of myoglobinuria, has been reported in cases of Russell’s viper
envenoming in Sri Lanka [7–10]. Elevation of plasma and urinary myoglobin concentrations
were reported in 19 Russell’s viper bite patients from Sri Lanka further suggesting the existence
of myotoxicity in Sri Lankan Russell’s viper patients [10]. A recent study of Sri Lankan
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Russell’s viper venom injected into mice reported an elevation in creatine kinase, also suggest-
ing that the venom is myotoxic in-vivo [11].
Myotoxicity is an important effect of snake envenoming and can manifest locally and sys-
temically [12]. Local muscle necrosis is a component of the local necrotic effects [12,13]. Sys-
temic myotoxicity has been reported following envenoming by some vipers [14,15], sea snakes
[16–18], Australasian elapids [19,20] and some Asian kraits [21,22]. Systemic myotoxicity
ranges in severity. Loss of functioning muscle cells due to myotoxicity can aggravate co-exist-
ing weakness due to neuromuscular block caused by neurotoxins. More importantly rhabdo-
myolysis can cause secondary acute kidney injury [23,24] and itself can result in life-
threatening hyperkalaemia due to extensive muscle cell damage [15].
Although many cytotoxic components in snake venoms may contribute to the development
of myotoxicity, the most important snake venom myotoxins are phospholipase A2 (PLA2) tox-
ins [12,25]. Three types of PLA2 myotoxins, commonly referred as Asp49, Ser49 and Lys49
PLA2, have been characterised in viperid venoms. Despite structural similarity, the latter two
types lack catalytic activity, and are referred to as ‘PLA2 like’ peptides [26–28]. It is important
to note that the enzymatic activity and the myotoxic activity of PLA2 myotoxins are indepen-
dent [29]. Myotoxic PLA2s cause muscle damage primarily by destruction of the sarcolemma
[12,30]. Several PLA2 toxins have been isolated from Sri Lankan Russell’s viper venom and bio-
chemically characterised, [31,32] Some of these PLA2 toxins contain a unique Serine residue at
the N-terminus (S-type), while others have an Asparagine residue at the N-terminus (N-type)
[32]. We have recently shown that the pre-synaptic neurotoxicity of the Sri Lankan Russell’s
viper venom is primarily due to one of the S-type PLA2 toxins, which we named U1-viperi-
toxin-Dr1a [33].
There are several gaps in our understanding of the myotoxicity associated with Sri Lankan
Russell’s viper envenoming. It is unclear if Sri Lankan Russell’s viper envenoming causes
severe myotoxicity and whether any resultant myotoxicity can be treated with Indian Polyva-
lent antivenom. Further, the in vitro myotoxicity of Sri Lankan Russell’s viper venom has not
been pharmacologically studied. This requires isolation and pharmacological characterisation
of the myotoxins from the venom. The present study aims to investigate the clinical severity of
myotoxicity from Russell’s viper envenoming and isolate the toxins responsible for this
activity.
Methods
Clinical study
Ethics, study setting and patients. We carried out a prospective cohort study of con-
firmed Russell’s viper bite patients aged over 16 years admitted to the Teaching Hospital Anu-
radhapura, Sri Lanka for a 14 month-period. The hospital is a tertiary care hospital which
admits over 1000 suspected snake bite cases annually. Ethics clearance for this study was
granted by the Human Research Ethics Committees of the University of Peradeniya (Approval
No: 2012/EC/63), Sri Lanka, Rajarata University of Sri Lanka (Approval No: ERC 2013/019)
and Monash University, Australia (Approval No: CF14/970–2014000404). Written informed
consent was obtained prior to the recruitment of all patients. For patients 16 and 17 years of
age, consent was also obtained from the patient’s parent or guardian. The recruitment of
patients to this cohort study has been previously described. [6]
Case authentication. Cases were authenticated by either positive identification of the
snake specimen involved as a Russell’s viper by AS, who is a herpetologist, or by detection of
the specific Russell’s viper venom antigens in blood samples of the patients using enzyme-
immunoassay (EIA).
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Clinical data collection and blood collection. Clinical examination of all patients was
undertaken on admission to hospital, 1 h, 4 h, 8 h, 12 h and 24 h post-bite, and then every 24 h
until discharge. In particular, muscle pain and tenderness, in the bitten limb (local myotoxi-
city) and the other limbs (generalized myotoxicity) were assessed as part of the clinical exami-
nations. Blood samples were collected from patients on admission and then 1 h, 4 h, 8 h, 12 h
and 24 h post-bite, and daily thereafter. All blood samples were immediately centrifuged,
serum aliquoted and frozen initially at -20˚C before transfer to -80˚C storage until they were
analysed.
Antivenom. Indian polyvalent antivenoms from VINS Bioproducts, India (batch num-
bers: 01AS11118, 1119, 1121, 1123, 3100, 4001, 4025, 4026, 4031) and BHARAT Serums and
Vaccines Ltd, India (batch number: A5311018) were used throughout the study period. In the
present cohort, the majority of patients received antivenom and a small proportion of these
received their first dose of antivenom at a primary care hospital, before being transferred to
the study hospital. The decision to administer antivenom was made solely by the treating phy-
sician, based on clinical and laboratory evidence of systemic envenoming. Patients were
administered between 10 to 20 vials of antivenom which is the standard dose. Antivenom was
administered in normal saline and infused over 1h. If an acute adverse reaction to antivenom
occurred, the infusion was stopped for 5 to 10 min and the patient treated with adrenaline,
antihistamines and corticosteroids, as per the treating clinicians.
Russell’s viper venom enzyme immunoassays. Measurement of venom in the samples
was carried out using a Russell’s viper venom specific Enzyme-Immunoassay (EIA) which has
been previously described [6,34,35]. In brief, rabbit IgG was raised against Russell’s viper
venom from Sri Lanka. Antibodies were bound to microplates as well as conjugated to biotin
as the detecting antibodies with streptavidin-horseradish peroxidase. The lower limit of detec-
tion for the assay was 2.5 ng/ml. In cases where no venom was detected in pre-antivenom sam-
ples or pre-antivenom samples were not available, the post-antivenom samples were subjected
to heat dissociation treatment and then tested for venom using the same EIA [35].
Serum creatine kinase (CK) assay. Creatine kinase (CK) was measured using the Thermo
Scientific Ltd CK-NAC reagent kit on stored frozen serum samples. Patient serum samples
were thawed and 15 μL added to 300 μL of reagent. After 120 s, the samples were read in a
plate reader (340 nm, 37˚C) for 3 min. An abnormal CK was defined as a concentration greater
than 300 U/l. A screening assay was done on all 24 h post-bite samples, or as close to this time
point as possible. If the screening assay was abnormal (> 300 U/L), then serial CK assays were
carried out for all samples available for that patient.
Data analysis. Continuous variables were reported as medians, range and interquartile
range (IQR). Associations between venom concentration and CK measurements were assessed
by Spearman’s correlation test. The CK concentrations between groups of patients was com-
pared with the Kruskal-Wallis test. Analysis of clinical data was done using PRISM, version
6.05 (GraphPad Software, Inc.).
Pharmacological study
Venom and antivenom. Freeze-dried Russell’s viper (D. russelii) venom from Sri Lanka
(pooled from both sexes, including juveniles) donated by Professor Ariaranee Gnanadasan
(Faculty of Medicine, University of Colombo, Sri Lanka) was used for this study. Venom was
dissolved in MilliQ water and stored at -20˚C until required. Protein quantification of the
venom, fractions and toxins was carried out using a BCA Protein Assay Kit (Thermo Fisher
Scientific, Rockford, IL, USA), as per the manufacturer’s instructions. The relative abundance
of the two isolated toxins was determined by the area under the chromatogram of the whole
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venom. Isolation of the two toxins was performed as described, from whole venom, using the
two chromatographic techniques. Here, the two toxins separately and the venom without the
two toxins were collected by multiple HPLC runs and pooled separately. Then, the three sam-
ples (i.e. venom without both toxins, and the two toxins) were dissolved separately. Based on
the protein assay, the protein/toxin amounts in the samples were determined. Then the differ-
ent combinations of the venom with and without individual toxins were made by mixing the
venom without the two toxins with appropriate toxin according to the proportion present in
the venom.
Indian polyvalent antivenom (VINS Bioproducts, Thimmapur, India; batch No:
01AS14035) was used for the study. The antivenom was reconstituted in 2 mL of sterile injec-
tion water. According to the manufacturer, 1/10 of the antivenom in a single vial neutralises
0.6 mg of Russell’s viper venom. For in-vitro studies examining the neutralisation of myotox-
ins, the required amount of antivenom was calculated based on the relative abundance of the
toxin in the venom.
In-vivo myotoxicity studies. Male Sprague–Dawley rats (300-360g) were anaesthetised
with sodium pentobarbital (60–100 mg/kg, i.p.) with additional anaesthetic being adminis-
tered during the experiment as required. An incision was made in the cervical region, the
carotid artery was cannulated for blood sample collection and the trachea intubated for artifi-
cial respiration, if required. The rats were kept on small animal surgery tables with their body
temperature maintained at 37˚C. Venom (250 μg/kg in 50 μl 0.9% saline, n = 4) was injected
into the gastrocnemius muscle of the left hind-limb. For control rats (n = 4), 50 μl 0.9% saline
was injected in the same location. Blood samples (500 μl) were collected into MiniCollect LH/
Gel separation tubes (Greiner bio-one), through the carotid cannula immediately before the
venom/saline injection and at 1.5, 3, 4.5 and 6 h post-injection. At 6 h, rats were humanely
killed with an overdose of sodium pentobarbitone. For the baseline measurements of CK,
blood samples of an additional seven ‘control’ (i.e. not envenomed) rats were used. Measure-
ment of CK was done using the same CK assay method used for human samples.
Liquid chromatography. Fractionation was performed using a Shimadzu (Kyoto, Japan)
system (LC-10ATvp pump and SPD-10AVP detector).
Size-exclusion chromatography: Crude venom (500 μg) was reconstituted in buffer A
(ammonium acetate; 0.1 M, pH 6.8). Venom was then separated using a Superdex G-75 col-
umn (13 μm; 10 mm × 300 mm; GE Healthcare, Uppsala, Sweden) equilibrated with buffer A.
Elution was performed at a flow rate of 0.5 ml/min and monitored at 280 nm. All fractions
were freeze-dried immediately and later screened using the chick biventer cervicis nerve-mus-
cle preparation (see 2.2.6 below) to identify those with myotoxicity.
Reverse-Phase HPLC (RP-HPLC): The fractions obtained from size exclusion chromatogra-
phy, which displayed in vitro myotoxicity, were subjected to further analysis using reverse-phase
HPLC. Size exclusion chromatography fractions were reconstituted in solvent A (0.1% trifluor-
oacetic acid [TFA]) and 2 mg of total protein was injected into a Phenomenex Jupiter semi-pre-
parative C18 column (250 mm ×10 mm; 5 μm; 300 A˚), equilibrated with solvent A. Fractions
were eluted using the following gradient of solvent B (90% Acetronitrile in 0.1% TFA): 0–30%
over 10 min, 30–70% for 10–50 min, and 70–0% for 50–55 min at a flow rate of 2.0 ml/min.
Matrix-Assisted Laser Desorption/Ionization (MALDI-TOF) Mass Spectrometry.
MALDI-TOF Mass Spectrometry analysis was performed in order to determine the intact
mass of the toxins, with an Applied Biosystems (Forster City, CA, USA) 4700 TOF TOF Prote-
omics Analyser, as described previously (Chaisakul et.al.). [36]
Amino acid sequence determination by Liquid Chromatogarphy-Mass Spectrometry
(LC-MS). Freeze-dried U1-viperitoxin-Dr1b dissolved in 100 mM ammonium bicarbonate
buffer, 2 mM DL-Dithiothreitol, incubated for 20 min at 65˚C and alkylated with 5 mM
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chloroacetamide. The protein mixture was digested with trypsin at 1:100 (w/w) ratio for 18 h
at 37˚C. The resulting peptides were desalted with Pierce C18 Spin columns (ThermoFisher
Scientific), dried, resuspended in 2% Acetronitrile, 0.1% TFA and analysed by LC-MS/MS
analysis as previously described [37]. The raw data acquired by the mass spectrometer was
converted into a centroided peaklist file using ProteoWizard (version 3.0.9967) [38]. The MS/
MS results were analysed with PMI-Byonic software (Protein Metrics, ver 2.8.14) against Uni-
prot serpents (taxID:8570) protein sequences (update 07/2016) using the following search
parameters: trypsin digestion with up to 2 missed cleavages, fixed cysteine alkylation, variable
methionine oxidation and asparagine and glutamine deamidation, precursor mass tolerance
10 ppm and fragment mass tolerance 20ppm.
PLA2 activity. PLA2 activity of the venom and U1-viperitoxin-Dr1b was determined
using a secretory PLA2 assay kit (Cayman Chemical, Ann Arbor, MI, USA) as described previ-
ously [33] and according to the manufacturer’s instructions.
Chick biventer cervicis nerve-muscle preparation. Male chickens (aged 4–10 days) were
humanely killed by exsanguination following CO2 inhalation. Biventer cervicis nerve-muscle
preparations were dissected and then mounted on wire tissue holders under 1 g resting tension in
5 ml organ baths. Tissues were maintained at 34˚C, bubbled with 95% O2 and 5% CO2, in physio-
logical salt solution of the following composition (mM); 118.4 NaCl, 4.7 KCl, 1.2 MgSO4, 1.2
KH2PO4, 2.5 CaCl2, 25 NaHCO3 and 11.1 glucose. Direct twitches were evoked by stimulating
the muscle belly (rate: 0.1 Hz; pulse duration: 2 ms) at supramaximal voltage (20–30 V) with the
two electrode loops directly encircling the muscle belly, using a Grass S88 stimulator (Grass
Instruments, Quincy, MA). Contractile responses of the tissues to KCl (40 mM for 30 s) was
obtained in the absence of muscle stimulation. Following that, direct stimulation of the muscle
was resumed. Selective stimulation of the muscle was ensured by abolishment of any indirect
twitches by the continual presence of adding d-tubocurarine (10 μM) to the organ bath. The prep-
arations were then stimulated for 30min, before the addition of venom or toxins. For antivenom
experiments, the tissues were equilibrated with antivenom for 20 min before the venom or toxin
was added. The preparation was exposed to the treatment/control until abolishment of direct
twitches or for a period of 3 h. At the conclusion of the experiment, KCl was re-added as above.
Data analysis and statistics. The quantity of the toxins in the venom was determined by
measuring the area under the curve of the size-exclusion and RP HPLC venom elution profiles.
Direct twitch responses and responses to KCl were measured via a Grass FTO3 force displace-
ment transducer and recorded on a PowerLab system (ADInstruments Pty Ltd., Australia).
Responses were expressed as percentages of their pre-venom/toxin values. T90 values (i.e. time
taken for 90% inhibition of the maximum twitch response to occur) were determined for the
two toxins. To compare the responses to exogenous agonists following the administration of
venom a one-way ANOVA was used. All ANOVAs were followed by Bonferroni’s multiple
comparison post-tests. Data are presented in the form of mean ± standard error of the mean
(S.E.M.) of n experiments. All statistical analyses and presentation of data were generated
using GraphPad Prism 6.05 software. For all statistical tests p < 0.05 was considered statisti-
cally significant.
Animal ethics. All animal experiments used in this study were approved by the Monash
University Animal Ethics Committee (Approval No: MARP/2014/097).
Results
Myotoxicity in authenticated cases
Clinical features of myotoxicity. Of the 245 authenticated Russell’s viper bite patients
recruited to the study, 177 (72.2%) had myalgia and 173 (70.6%) tenderness in the bitten limb
Myotoxicity in Sri Lankan Russell’s Viper Envenoming
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(local myotoxicity). Thirty-five patients (14.2%) and 29 patients (11.8%) had generalized myal-
gia and generalized muscle tenderness, respectively. Changes in local and generalized myalgia
and muscle tenderness over time among the study participants is shown in Fig 1A and 1B.
Myalgia and muscle tenderness resolved in over 80% of the patients by day 4. Six patients
(2.4%) had dark coloured urine observed between 12 and 48 h after the bite. The clinico-epide-
miological data related this cohort of patients is described in the Table 1.
Serum creatine kinase concentrations. Serum CK concentrations in 24 h post-bite sam-
ples of 219 patients ranged from 2 to 1019 U/l (median: 110 U/l). Samples of the remaining 26
patients were unavailable. Of the 219 patients, 37 patients (16.8%) had CK concentrations
above 300 U/l. The median 24 h post-bite CK concentrations of patients who had no clinical
features of myotoxicity was 58 U/l (IQR: 34–183 U/l), compared to 137 U/l (IQR: 56–285 U/l)
in those with features of local myotoxicity, and 107 U/l (IQR: 71–226 U/l) in patients who had
features of systemic myotoxicity (p = 0.049; Kruskal Wallis test; Fig 2A). There was no statisti-
cally significant association between 24 h serum CK concentration and peak venom concentra-
tions (Spearman’s correlation; p = 0.48; Fig 2B). Similarly, there was no relationship between
the time delay from the snakebite to first dose of antivenom and 24 h serum CK (Fig 2C). Of
Fig 1. Clinical features of myotoxicity in 245 confirmed Sri Lankan Russell’s viper envenomings (a), the presence of localised and generalised
myalgia over time; (b), the presence of localised and generalised muscle tenderness over time. Note: data of all 245 patients were not available at
any given time because some patients were admitted later than the time point or discharged before the time point, or the clinical assessment of the
patient was not possible at that time point because the patient was sedated, unconscious or transported away for investigations.
doi:10.1371/journal.pntd.0005172.g001
Table 1. Clinical and epidemiological data of the 245 patients recruited for the present study.
Age (Median, range in years) 41 (16–70)
Sex (males) 171 (70%)
Length of the snake specimen (median, range) 32.3 (20.4–110.5) cm
Time since bite to reach the study hospital (Median, IQR) 2.5 (1.75–4.0) h
Peak venom concentration (median, range) 25 (2.5–2316) ng/ml
Number of patients with coagulopathy 166 (68%)
Number of patients with neurotoxicity 130 (53%)
Number of patients received antivenom 190 (78%)
Time from snakebite to antivenom (Median, IQR) 3.75 (2.75–5.0) h
Number of antivenom vials received (median, range) 20 (10–90)
Length of hospital stay 3 (2–31) days
doi:10.1371/journal.pntd.0005172.t001
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Fig 2. Serum creatine kinase (CK) concentrations in 219 study participants: (a) Scatter plot comparing the CK concentrations (at 24 h
post bite) of patients with no features, patients with features of local myotoxicity (myalgia or tenderness) and patients with features of
systemic myotoxicity (p = 0.049; Kruskal-Wallis test); (b), peak serum concentrations of CK versus venom in 37 patients who had CK
>300U/l at 24 h post-bite (Spearman’s correlation; p = 0.48); (c), CK concentration at 24 h versus time from the snakebite to the first
antivenom dose in 178 patients who received antivenom (note: 12 patients who received antivenom had no CK due to the unavailability
Myotoxicity in Sri Lankan Russell’s Viper Envenoming
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0005172 December 2, 2016 8 / 18
the 190 patients who were given antivenom, CK concentrations at 24 h were available in 178
patients. Of these, 135 patients were given antivenom within 6 h and 31 of these developed a
CK> 300 U/l at 24 h, compared to 31 patients who received antivenom after 6 h with 6 devel-
oping a CK> 300 U/l at 24 h.
Only three of the six patients with dark coloured urine had CK concentrations above 300
U/l (404, 633 and 856 U/l,). However, red blood cells were reported in three of these six
patients (S1 Table). The dark coloured urine in Russell’s viper envenoming could be due to
myoglobinuria, haemoglobinuria, haematuria or a combination of all these.
The serial CK concentrations of the 37 patients with high CK had a median peak value of
666 U/l (maximum: 1066). In most patients, CK reached a peak in 24 h after the bite (Fig 2D).
By the time CK started to rise, the venom concentrations in these patients had already
decreased, and in most cases was lower than the level of detection (Fig 2E).
In-vivo myotoxic effects in anaesthetised rats
The plasma CK concentrations of rats injected with Sri Lankan Russell’s viper venom 250 μg/
kg (i.m.) were not different tocontrol rats and were within the normal range until 6 h of the
venom injection (S1 Fig).
Isolation and biochemical characterisation of U1-viperitoxin-Dr1a and
U1-viperitoxin-Dr1b
Liquid Chromatography. Eight major fractions were identified with size-exclusion chro-
matography of the crude venom of Russell’s viper (Fig 3A). Peak E, eluting around 33 min
showed marked myotoxicity in the chick biventer cervicis nerve-muscle preparation. Peak E
was further analysed and fractionated using RP-HPLC (Fig 4B). In vitro myotoxicity was
largely confined to two peaks with retention times of 31 min and 38 min, respectively (Fig 3B).
The former venom component eluting at 31 min was subsequently isolated as U1-viperitoxin-
Dr1b, and constituted 22.7% (SD: 1.2; n = 10) of the crude venom, based on the area under the
curve of the size exclusion chromatography and RP-HPLC profiles of the venom. The compo-
nent eluting at 38 min was named U1-viperitoxin-Dr1a, a PLA2 toxin which has been previ-
ously characterised biochemically and found to be the major neurotoxin (with a relative
abundance of 19.2%) in Sri Lankan Russell’s viper venom [33].
Intact protein analysis of U1-viperitoxin-Dr1b by MALDI-TOF. Analysis of U1-viperi-
toxin-Dr1b by MALDI-TOF mass spectrometry indicated a single species with a mass/charge
ratio of 13564 Da (Fig 4). A doubly charged ion with a mass/charge ratio of 6779.8 Da was also
observed.
LC-MS/MS identification of U1-viperitoxin-Dr1b by LC-MS. LC-MS/MS analysis of
U1-viperitoxin-Dr1b identified it as Basic phospholipase. The obtained sequence coverage was
100% showing that the toxin is exactly identical to Basic phospholipase A2 VRV-PL-VIIIa
(SwissProt: P59071, Entry name: PA2B8_DABRR) (see S2 Fig and S2 Table).
PLA2 activity of U1-viperitoxin-Dr1b. PLA2 activity of U1-viperitoxin-Dr1b was 1139
(+/- 19) μmol/min/mg.
Pharmacological investigation of the myotoxicity. Sri Lankan Russell’s viper venom
caused concentration-dependent inhibition of direct twitches in the chick biventer nerve mus-
cle preparation (Fig 5A) and inhibited the response to 40 mM KCl (Fig 5B). However, high
of the sample at 24 h); (d), plots of the CK concentrations versus time since bite for the 37 patients; (e), plots of the venom
concentrations versus time for the 37 patients.
doi:10.1371/journal.pntd.0005172.g002
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venom concentration such as 80μg/ml did not completely abolish either the direct twitches or
the response to KCl, even after 3 h. U1-viperitoxin-Dr1b (Fig 5C) and U1-viperitoxin-Dr1a
(Fig 5D) concentration-dependently inhibited the direct twitches and also inhibited the
Fig 3. Chromatograms of Sri Lankan Russell’s viper venom and fractions (a), Size-exclusion chromatogram of the
whole venom on Superdex G75 column; (b), Reverse Phase High Performance Liquid Chromatogram (RP-HPLC)
of the fraction ‘E’ on Jupiter C18 semi-preparative column. Note: the peaks eluting at 31 and 38 min in RP-HPLC
chromatograms are U1-viperitoxin-Dr1b and U1-viperitoxin-Dr1a, respectively.
doi:10.1371/journal.pntd.0005172.g003
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response to KCl (Fig 5E). When the response to KCl was compared between the crude venom
50μg/ml, each of the two toxins of the same amount of venom individually, a combination of
the two toxins, and the whole venom without individual or both toxins, removal of the two
toxins led to a loss of all myotoxicity from the venom (Fig 5F). Antivenom, at the recom-
mended concentrations, did not neutralise the myotoxic effect of the venom (Fig 5B)
Discussion
The present study demonstrates that myotoxicity seen in humans following Sri Lankan Rus-
sell’s viper envenoming is mild, based on the relatively low frequency of generalized myotoxic
features and only a very mild elevation in CK. There were small but statistically significant
association between clinical features of myotoxicity and the 24 h CK measurements. The rats
injected intramuscularly with Sri Lankan Russell’s viper venom did not show an elevation of
CK within the first 6 h. Although Sri Lankan Russell’s viper venom displays concentration-
dependent myotoxic effects in-vitro, very high venom concentrations (i.e. >50 μg/ml) are
required to completely inhibit direct twitches in the chick biventer nerve-muscle preparation
and the response to KCl. Antivenom at recommended concentrations was unable to neutralise
the myotoxic properties of the venom in-vitro. The myotoxicity of the whole venom appears to
be due to two abundant PLA2 toxins in the venom, U1-viper1toxin-Dr1a and U1-viperitoxin-
Dr1b (named herein), which both have in vitro myotoxic activity, but only at very high concen-
trations (3 μM).
Fig 4. Intact protein analysis chromatogram of MALDI-TOF: the intact mass of U1-viperitoxin-Dr1b is 13.564 kDa.
doi:10.1371/journal.pntd.0005172.g004
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Fig 5. In-vitro myotoxicity of whole venom (Venom) of Sri Lankan Russell’s viper, U1-viperitoxin-Dr1a (Toxin A) and U1-viperitoxin-Dr1b
(Toxin B) compared to controls: (a), Concentration-dependent inhibition of direct twitches in chick biventer nerve-muscle preparation by
whole venom. (* the 80μg/ml venom group is significantly different from 50 μg/ml group as well as the control group at 170 min; p<0.05: One-
way ANOVA followed by Bonferroni’s post-hoc test, n = 4.). (b), Effect of 80μg/ml venom alone and in the presence of antivenom on the
Myotoxicity in Sri Lankan Russell’s Viper Envenoming
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0005172 December 2, 2016 12 / 18
Features of systemic myotoxicity such as generalized muscle tenderness and myalgia, and
dark coloured urine were observed in less than 15% of the patients. In addition, three of the six
patients with dark coloured urine did not have 24 h CK concentrations outside the normal
limit, so the dark urine was more likely due to macroscopic haematuria (due to haemorrhage)
which occurs with Russell’s viper envenoming. Peak CK concentrations were abnormally high
in less than 17% of patients, and even in these cases there were only modest elevations with the
median and maximum being 666 and 1066 U/l, respectively. In comparison, the reported
median peak CK values following envenoming by mulga snakes and tiger snakes in Australia
were 3100 U/l [20] and 4749 U/l [19], with severe myotoxicity being associated with CK values
over 100,000 U/L. This means that myotoxicity in Russell’s viper envenoming is uncommon
and mild when it occurs compared to other myotoxic snakes. The median 24 h CK concentra-
tions were higher in symptomatic patients demonstrating that the clinical features were consis-
tent with biochemical evidence of mild muscle injury.
Anaesthetised rats injected with venom showed no significant increase in serum CK con-
centrations compared to saline injected rats, even 6 h after the venom injection. Assuming that
the blood volume of a rat with a body weight of 330g is approximately 25 ml, the maximum
serum venom concentration that this venom dose (i.e. 250 μg/kg), with 100% systemic absor-
bance, could give rise to is 3300 ng/ml. This venom concentration is greater than the maxi-
mum venom concentration observed in the Russell’s viper envenomed patients in this study,
hence the venom dose used for the envenoming is clinically relevant. The absence of a signifi-
cant CK rise in the envenomed rats during the 6 h observation period may be due to a com-
bined effect of the weak myotoxicity of the venom and the period of observation being too
short to observe any CK elevation. These results are not in agreement with the previously
reported high CK concentrations (mean: 16,000 U/l) in mice, 3 h after the intramuscular injec-
tion of 5 μg (250 μg/kg dose in 20 g mouse) of Sri Lankan Russell’s viper venom [11], despite
similar venom doses in the two studies. The reason for the discrepancy is unclear but such a
large early increase in CK concentrations is unusual and the mouse model has not previously
been validated.
The clinical findings were consistent with the in vitro studies in which two low potency
myotoxins were found to be relatively abundant in the venom. Very high venom concentra-
tions up to 80 μg/ml (80 times higher than the maximum peak venom concentration observed
in envenomed patients) were required to decrease the direct twitch force by two thirds within
3 h. The low potency of both myotoxins was evident from the fact that high concentrations
(3 μM) were required for significant in-vitro myotoxic activity. Venom with these two toxins
removed did not cause myotoxicity confirming that these toxins are the only major myotoxins
in Sri Lankan Russell’s viper venom.
Three previous studies between 1984 and 2000 report much higher rates of myotoxicity,
based mainly on myalgia and muscle tenderness. In 1984, Jeyarajah [9] reported myotoxic
response of the muscle to 40mM KCl. (* significantly different compared to the response to KCl obtained prior to the addition of venom;
p<0.05: paired t-test) (c), Concentration-dependent inhibition of the direct twitches in chick biventer nerve-muscle preparation by
U1-viperitoxin-Dr1b. *(twitch height significantly lower than the control group: p<0.05, one-way ANOVA followed by Bonferroni’s post-hoc
test; n = 3–5); (d), Concentration-dependent inhibition of the direct twitches in chick biventer nerve-muscle preparation by U1-viperitoxin-
Dr1a. (* twitch height significantly lower than the control group: p<0.05, one-way ANOVA followed by Bonferroni’s post-hoc test; n = 3–5);
(e), Effect of 3 μM U1-viperitoxin-Dr1a (B) and U1-viperitoxin-Dr1b (M) towards the response of the muscle for 40 mMKCl. (* the KCl
response of the venom with and without antivenom, at 170min were significantly reduced compared to the initial responses; p<0.05: paired t-
test); (f), Effect of 50μg/ml whole venom versus U1-viperitoxin-Dr1a, U1-viperitoxin-Dr1b, venom without U1-viperitoxin-Dr1a, venom without
U1-viperitoxin-Dr1b, both toxins together, venom without both toxins of a same amount of venom in 5ml organ bath towards the response of
the muscle for 40 mMKCl. * (* the KCl response is significantly lower compared to the control group at 170 min; p<0.05: one-way ANOVA
followed by Bonferroni’s post-hoc test; n = 3–5).
doi:10.1371/journal.pntd.0005172.g005
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symptoms in 77% of the cases but no biochemical confirmation of myotoxicity. This study
included only severe envenoming with 19/22 with acute kidney injury and 6 deaths. In 1988,
Phillips et. al. [10] reported myotoxic symptoms in 32% of the cases, but again this only
included more severe envenoming (4/23 died). The mean venom concentration of 375 ng /ml
(range: 16.5–702 ng/ml) [10] was much higher compared to the median peak venom concen-
tration of 25 ng/ml (range:2.5–2316 ng/ml) in our study [6]. Phillips et al. reported serum and
urine myoglobin, which are difficult to interpret because no studies have correlated these mea-
surements with outcomes. They detected myoglobin in the plasma of all 19 patients tested
(range: 100->8000; median: 2745, normal value:<50 ng/ml) and in the urine in 14 of 18
patients (110 to>16 000; median: 4000; normal:<21 ng/ml)[10]. Although these appear to be
high, much higher values are reported in Australian mulga snake envenoming, where urinary
myogolobin values in three patients were 4129, 28200 and 127000 ng/ml[20]. In a larger study
of 336 patients in 2000 by Kularatne et al [7] there were 47 patients (14%) with myotoxicity
based on generalised muscle tenderness. This is consistent with our study in terms of clinical
effects but they did not provide any biochemical confirmation. Our 245 patients are typical of
current patients. They had high circulating peak venom concentrations with a median of
25ng/ml, with 24 patients having venom concentrations >1000 ng/ml [6]. Further, nearly all
had local envenoming, 68% had coagulopathy (half with bleeding manifestations), and 53%
had neuromuscular paralysis [6]. Therefore, the mild myotoxic effects in Sri Lankan Russell’s
viper envenoming are most likely due to the weak myotoxicity of the venom.
In patients with Australian Mulga snake (Pseudechis australis) envenoming, a delay in anti-
venom treatment has led to an increase in the severity of the myotoxicity [20]. Since there was
no control group of patients who did not receive antivenom in this study, it could be argued
that the weak myotoxicity observed in Sri Lankan Russell’s viper envenoming is due to an
effect of antivenom. However, there was no association between the delay in antivenom treat-
ment and the number of patients having CK >300 U/l, indicating that the weak myotoxicity
observed in the patients is not due to an effect of the antivenom.
Indian Polyvalent antivenom was used at concentrations equivalent to the tested venom as
recommended by the manufacturer. At these concentrations antivenom failed to prevent the
myotoxic effects of Sri Lankan Russell’s viper venom in-vitro. Although this may be due to the
low efficacy of the antivenom against the myotoxins [39], testing higher antivenom concentra-
tions was not possible due to the practical limitations of increasing antivenom concentration
in the tissue organ bath environment without affecting the osmolarity of the physiological salt
solution. It was therefore not possible to determine the efficacy of the Indian polyvalent anti-
venom to neutralise the myotoxic effects of Sri Lankan Russell’s viper venom, because such a
large amount of venom was required to cause myotoxicity requiring very high concentrations
of antivenom.
Of the several ‘s’ type PLA2 toxins isolated from Sri Lankan Russell’s viper venom,
VRV-PL-VIIIa [40] has 100% match with the aligned trypsin digested peptide fragments of
U1-viperitoxin-Dr1b. The N-terminal sequence of the first 50 amino acids of the toxin ‘P1’
[31] and the N-terminal sequence of first 21 amino acids of the toxin PLA2 4 [32] are a 100%
match for the sequence of U1-viperitoxin-Dr1b. Following the suggested rational nomencla-
ture for toxins [41], and given that the 94% sequence homology of the toxin with U1-viperi-
toxin-Dr1a[33], we have named the above toxin as U1-viperitoxin-Dr1b (Fig 6).
The recent study on the venom proteome of the Sri Lankan Russell’s viper [11] reported
that five PLA2 toxins make up a relative abundance of 35% of the whole venom, with
VRV-PL-VIIIa (U1-viperitoxin-Dr1b) making 13.9% (as opposed to 22.2% in our study) of
the whole venom. However, the same study did not match a PLA2 with VRV-PL-V (U1-
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viperitoxin-Dr1a), which makes 19.2% of the venom in our analysis as previously published
[33].
In conclusion, myotoxicity in Sri Lankan Russell’s viper envenoming is mild and non-life
threatening, as evident from the low frequency of generalized myotoxicity and low concentra-
tions of serum creatine kinase in envenomed patients. The whole venom of Sri Lankan Rus-
sell’s viper has weak myotoxic properties in-vitro. Two PLA2 toxins, U1-viperitoxin-Dr1a and
U1-viperitoxin-Dr1b that make 42% of the whole venom, are the major myotoxins in the
venom, but display weak myotoxicity. There is a small possibility that myotoxicity may occur
in patients with severe Sri Lankan Russell’s viper envenoming in which antivenom is delayed.
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